(AVTR) Avantor - Ratings and Ratios
Chemicals, Lab Products, Equipment, Services, Consumables
AVTR EPS (Earnings per Share)
AVTR Revenue
Description: AVTR Avantor
Avantor Inc (NYSE:AVTR) is a leading provider of mission-critical products and services to various industries, including biopharma, healthcare, education, and advanced technologies. The companys diverse portfolio includes materials and consumables, equipment and instrumentation products, and services such as onsite lab and production support, procurement and sourcing, and biopharmaceutical material scale-up and development.
From a financial perspective, Avantors market capitalization stands at approximately $8.4 billion, indicating a significant presence in the life sciences tools and services sector. The companys price-to-earnings ratio is around 11.87, with a forward P/E of 12.90, suggesting a relatively stable valuation. Additionally, Avantors return on equity (RoE) is 12.42%, indicating a decent level of profitability.
To further analyze Avantors performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating cash flow can be examined. For instance, a review of the companys historical financials reveals a steady increase in revenue, driven by a combination of organic growth and strategic acquisitions. Furthermore, Avantors gross margin has remained relatively stable, indicating a consistent ability to maintain pricing power and manage costs. The companys operating cash flow has also shown a positive trend, enabling it to invest in growth initiatives and reduce debt.
From a trading perspective, Avantors stock has experienced a significant decline over the past 52 weeks, with a high of $27.70 and a low of $11.94. The current price of $13.60 is closer to the lower end of this range, potentially indicating a buying opportunity. Technical indicators such as the 20-day, 50-day, and 200-day simple moving averages (SMA) can provide further insights into the stocks trend and momentum.
AVTR Stock Overview
| Market Cap in USD | 8,992m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2019-05-17 |
AVTR Stock Ratings
| Growth Rating | -80.5% |
| Fundamental | 47.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -60.6% |
| Analyst Rating | 3.76 of 5 |
AVTR Dividends
Currently no dividends paidAVTR Growth Ratios
| Growth Correlation 3m | -51.7% |
| Growth Correlation 12m | -91.8% |
| Growth Correlation 5y | -71.8% |
| CAGR 5y | -16.56% |
| CAGR/Max DD 3y | -0.28 |
| CAGR/Mean DD 3y | -1.01 |
| Sharpe Ratio 12m | -0.97 |
| Alpha | 0.11 |
| Beta | 0.663 |
| Volatility | 45.78% |
| Current Volume | 8410.5k |
| Average Volume 20d | 8554k |
| Stop Loss | 12.1 (-4.8%) |
| Signal | 1.30 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (687.4m TTM) > 0 and > 6% of Revenue (6% = 399.9m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -1.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.92% (prev 12.67%; Δ -13.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 681.8m <= Net Income 687.4m (YES >=105%, WARN >=100%) |
| Net Debt (3.79b) to EBITDA (1.41b) ratio: 2.69 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (681.8m) change vs 12m ago -0.12% (target <= -2.0% for YES) |
| Gross Margin 33.25% (prev 33.71%; Δ -0.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.34% (prev 53.77%; Δ -1.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.61 (EBITDA TTM 1.41b / Interest Expense TTM 179.2m) >= 6 (WARN >= 3) |
Altman Z'' 2.11
| (A) -0.00 = (Total Current Assets 2.51b - Total Current Liabilities 2.58b) / Total Assets 12.78b |
| (B) 0.18 = Retained Earnings (Balance) 2.33b / Total Assets 12.78b |
| (C) 0.08 = EBIT TTM 1.01b / Avg Total Assets 12.74b |
| (D) 0.97 = Book Value of Equity 6.29b / Total Liabilities 6.49b |
| Total Rating: 2.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.09
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 4.35% = 2.17 |
| 3. FCF Margin 8.34% = 2.08 |
| 4. Debt/Equity 0.67 = 2.28 |
| 5. Debt/Ebitda 3.01 = -1.78 |
| 6. ROIC - WACC (= 2.11)% = 2.63 |
| 7. RoE 11.51% = 0.96 |
| 8. Rev. Trend -86.23% = -6.47 |
| 9. EPS Trend -76.01% = -3.80 |
What is the price of AVTR shares?
Over the past week, the price has changed by -0.94%, over one month by -0.39%, over three months by -5.36% and over the past year by -53.27%.
Is Avantor a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AVTR is around 9.42 USD . This means that AVTR is currently overvalued and has a potential downside of -25.89%.
Is AVTR a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.1 | 10.6% |
| Analysts Target Price | 14.1 | 10.6% |
| ValueRay Target Price | 10.3 | -19.3% |
Last update: 2025-09-06 04:32
AVTR Fundamental Data Overview
CCE Cash And Equivalents = 449.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 12.6827
P/E Forward = 12.9534
P/S = 1.349
P/B = 1.3904
Beta = 0.976
Revenue TTM = 6.67b USD
EBIT TTM = 1.01b USD
EBITDA TTM = 1.41b USD
Long Term Debt = 2.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.25b USD (from shortTermDebt, last quarter)
Debt = 4.24b USD (Calculated: Short Term 1.25b + Long Term 2.99b)
Net Debt = 3.79b USD (from netDebt column, last quarter)
Enterprise Value = 12.79b USD (8.99b + Debt 4.24b - CCE 449.4m)
Interest Coverage Ratio = 5.61 (Ebit TTM 1.01b / Interest Expense TTM 179.2m)
FCF Yield = 4.35% (FCF TTM 555.9m / Enterprise Value 12.79b)
FCF Margin = 8.34% (FCF TTM 555.9m / Revenue TTM 6.67b)
Net Margin = 10.31% (Net Income TTM 687.4m / Revenue TTM 6.67b)
Gross Margin = 33.25% ((Revenue TTM 6.67b - Cost of Revenue TTM 4.45b) / Revenue TTM)
Tobins Q-Ratio = 2.03 (Enterprise Value 12.79b / Book Value Of Equity 6.29b)
Interest Expense / Debt = 1.02% (Interest Expense 43.4m / Debt 4.24b)
Taxrate = 16.68% (142.4m / 853.9m)
NOPAT = 837.7m (EBIT 1.01b * (1 - 16.68%))
Current Ratio = 0.98 (Total Current Assets 2.51b / Total Current Liabilities 2.58b)
Debt / Equity = 0.67 (Debt 4.24b / last Quarter total Stockholder Equity 6.29b)
Debt / EBITDA = 3.01 (Net Debt 3.79b / EBITDA 1.41b)
Debt / FCF = 7.63 (Debt 4.24b / FCF TTM 555.9m)
Total Stockholder Equity = 5.97b (last 4 quarters mean)
RoA = 5.38% (Net Income 687.4m, Total Assets 12.78b )
RoE = 11.51% (Net Income TTM 687.4m / Total Stockholder Equity 5.97b)
RoCE = 11.22% (Ebit 1.01b / (Equity 5.97b + L.T.Debt 2.99b))
RoIC = 8.13% (NOPAT 837.7m / Invested Capital 10.31b)
WACC = 6.02% (E(8.99b)/V(13.23b) * Re(8.46%)) + (D(4.24b)/V(13.23b) * Rd(1.02%) * (1-Tc(0.17)))
Shares Correlation 3-Years: 54.55 | Cagr: 0.03%
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.63% ; FCFE base≈628.0m ; Y1≈584.3m ; Y5≈536.5m
Fair Price DCF = 13.08 (DCF Value 8.92b / Shares Outstanding 681.7m; 5y FCF grow -8.84% → 3.0% )
EPS Correlation: -76.01 | EPS CAGR: -11.90% | SUE: -0.69 | # QB: 0
Revenue Correlation: -86.23 | Revenue CAGR: -3.50% | SUE: N/A | # QB: None
Additional Sources for AVTR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle